{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T20:43:58Z","timestamp":1774471438336,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"British Heart Foundation (GB)","award":["PG\/09\/102"],"award-info":[{"award-number":["PG\/09\/102"]}]},{"name":"British Heart Foundation (GB)","award":["FS\/11\/36\/28872"],"award-info":[{"award-number":["FS\/11\/36\/28872"]}]},{"DOI":"10.13039\/501100000361","name":"Diabetes UK","doi-asserted-by":"publisher","award":["RD06\/0003272"],"award-info":[{"award-number":["RD06\/0003272"]}],"id":[{"id":"10.13039\/501100000361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["G0601215"],"award-info":[{"award-number":["G0601215"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12933-016-0386-5","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T12:13:56Z","timestamp":1460636036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Metabolically-inactive glucagon-like peptide-1(9\u201336)amide confers selective protective actions against post-myocardial infarction remodelling"],"prefix":"10.1186","volume":"15","author":[{"given":"Emma","family":"Robinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchel","family":"Tate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"McPeake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla M.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin S.","family":"Edgar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Calderwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian D.","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara J.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Grieve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,14]]},"reference":[{"key":"386_CR1","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/bph.12943","volume":"172","author":"M Tate","year":"2015","unstructured":"Tate M, Chong A, Robinson E, Green BD, Grieve DJ. Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol. 2015;172:721\u201336.","journal-title":"Br J Pharmacol"},{"key":"386_CR2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1161\/hh1701.095716","volume":"89","author":"MG VilaPetroff","year":"2001","unstructured":"VilaPetroff MG, Egan JM, Wang X, Sollott SJ. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res. 2001;89:445\u201352.","journal-title":"Circ Res"},{"key":"386_CR3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1172\/JCI0215595","volume":"110","author":"H Yamamoto","year":"2002","unstructured":"Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002;110:43\u201352.","journal-title":"J Clin Invest"},{"key":"386_CR4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.abb.2008.08.001","volume":"478","author":"BD Green","year":"2008","unstructured":"Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys. 2008;478:136\u201342.","journal-title":"Arch Biochem Biophys"},{"key":"386_CR5","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","volume":"117","author":"K Ban","year":"2008","unstructured":"Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117:2340\u201350.","journal-title":"Circulation"},{"key":"386_CR6","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1210\/en.2003-0007","volume":"144","author":"R Gros","year":"2003","unstructured":"Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN, Parker TG, Huang Q, Drucker DJ, Husain M. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology. 2003;144:2242\u201352.","journal-title":"Endocrinology"},{"key":"386_CR7","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1161\/01.CIR.0000139339.85840.DD","volume":"110","author":"LA Nikolaidis","year":"2004","unstructured":"Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004;110:955\u201361.","journal-title":"Circulation"},{"key":"386_CR8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1161\/CIRCHEARTFAILURE.108.766402","volume":"1","author":"I Poornima","year":"2008","unstructured":"Poornima I, Brown S, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic glucagon-like peptide-1 (GLP-1) infusion sustains LV systolic function and prolongs survival in the spontaneously hypertensive-heart failure prone rat. Circ Heart Fail. 2008;1:153\u201360.","journal-title":"Circ Heart Fail"},{"key":"386_CR9","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cardfail.2006.08.211","volume":"12","author":"GG Sokos","year":"2006","unstructured":"Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12:694\u20139.","journal-title":"J Card Fail"},{"key":"386_CR10","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.2337\/db09-0955","volume":"59","author":"M Sauve","year":"2010","unstructured":"Sauve M, Ban K, Momen MA, Zhou YQ, Henkelman RM, Husain M, Drucker DJ. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes following myocardial infarction in mice. Diabetes. 2010;59:1063\u201373.","journal-title":"Diabetes"},{"key":"386_CR11","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2337\/db08-1193","volume":"58","author":"MH Noyan-Ashraf","year":"2009","unstructured":"Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58:975\u201383.","journal-title":"Diabetes"},{"key":"386_CR12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00395-014-0426-9","volume":"109","author":"A Goodwill","year":"2014","unstructured":"Goodwill A, Tune J, Noblet J, Conteh A, Sassoon D, Casalini E, Mather K. Glucagon-like peptide-1 (7\u201336) but not (9\u201336) augments cardiac output during myocardial ischemia via a Frank\u2013Starling mechanism. Basic Res Cardiol. 2014;109:426.","journal-title":"Basic Res Cardiol"},{"key":"386_CR13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12933-014-0115-x","volume":"13","author":"M Chen","year":"2014","unstructured":"Chen M, Angeli FS, Shen YT, Shannon RP. GLP-1 (7\u201336) amide restores myocardial insulin sensitivity and prevents the progression of heart failure in senescent beagles. Cardiovasc Diabetol. 2014;13:115.","journal-title":"Cardiovasc Diabetol"},{"key":"386_CR14","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2337\/diacare.27.3.699","volume":"27","author":"AG Bertoni","year":"2004","unstructured":"Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004;27:699\u2013703.","journal-title":"Diabetes Care"},{"key":"386_CR15","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/j.1476-5381.2009.00376.x","volume":"157","author":"DJ Grieve","year":"2009","unstructured":"Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol. 2009;157:1340\u201351.","journal-title":"Br J Pharmacol"},{"key":"386_CR16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1475-2840-9-76","volume":"9","author":"Q Liu","year":"2010","unstructured":"Liu Q, Anderson C, Broyde A, Polizzi C, Fernandez R, Baron A, Parkes D. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol. 2010;9:76.","journal-title":"Cardiovasc Diabetol"},{"key":"386_CR17","doi-asserted-by":"crossref","first-page":"E630","DOI":"10.1152\/ajpendo.00109.2014","volume":"307","author":"M DeNicola","year":"2014","unstructured":"DeNicola M, Du J, Wang Z, Yano N, Zhang L, Wang Y, Qin G, Zhuang S, Zhao TC. Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium. Am J Physiol Endocrinol Metab. 2014;307:E630\u201343.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"386_CR18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00395-015-0476-7","volume":"110","author":"E Robinson","year":"2015","unstructured":"Robinson E, Cassidy R, Tate M, Zhao Y, Lockhart S, Calderwood D, Church R, McGahon M, Brazil D, McDermott B, Green B, Grieve D. Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix. Basic Res Cardiol. 2015;110:20.","journal-title":"Basic Res Cardiol"},{"key":"386_CR19","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","volume":"57","author":"H Bugger","year":"2014","unstructured":"Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014;57:660\u201371.","journal-title":"Diabetologia"},{"key":"386_CR20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0014-2999(96)00795-9","volume":"318","author":"LB Knudsen","year":"1996","unstructured":"Knudsen LB, Pridal L. Glucagon-like peptide-1-(9\u201336) amide is a major metabolite of glucagon-like peptide-1-(7\u201336) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol. 1996;318:429\u201335.","journal-title":"Eur J Pharmacol"},{"key":"386_CR21","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.2337\/db15-0084","volume":"64","author":"F Giacco","year":"2015","unstructured":"Giacco F, Du X, Carratu A, Gerfen GJ, D\u2019Apolito M, Giardino I, Rasola A, Marin O, Divakaruni AS, Murphy AN, Shah MS, Brownlee M. GLP-1 cleavage product reverses persistent ROS generation after transient hyperglycemia by disrupting an ROS-generating feedback loop. Diabetes. 2015;64:3273\u201384.","journal-title":"Diabetes"},{"key":"386_CR22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/FJC.0000000000000120","volume":"64","author":"Z Bayram","year":"2014","unstructured":"Bayram Z, Nacitarhan C, Ozdem SS. Effects of glucagon-like peptide-1 in diabetic rat small resistance arteries. J Cardiovasc Pharmacol. 2014;64:277\u201384.","journal-title":"J Cardiovasc Pharmacol"},{"key":"386_CR23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.regpep.2007.10.001","volume":"146","author":"DP Sonne","year":"2008","unstructured":"Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9\u201336) amide against ischemia-reperfusion injury in rat heart. Regul Pept. 2008;146:243\u20139.","journal-title":"Regul Pept"},{"key":"386_CR24","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1210\/en.2009-1197","volume":"151","author":"K Ban","year":"2010","unstructured":"Ban K, Kim KH, Cho CK, Sauve M, Diamandis EP, Backx PH, Drucker DJ, Husain M. Glucagon-like peptide (GLP)-1(9\u201336)amide-mediated cytoprotection is blocked by exendin(9\u201339) yet does not require the known GLP-1 receptor. Endocrinology. 2010;151:1520\u201331.","journal-title":"Endocrinology"},{"key":"386_CR25","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317\u201326.","journal-title":"N Engl J Med"},{"key":"386_CR26","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327\u201335.","journal-title":"N Engl J Med"},{"key":"386_CR27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/HYPERTENSIONAHA.107.101980","volume":"51","author":"YH Looi","year":"2008","unstructured":"Looi YH, Grieve DJ, Siva A, Walker SJ, Anilkumar N, Cave AC, Marber M, Monaghan MJ, Shah AM. Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension. 2008;51:319\u201325.","journal-title":"Hypertension"},{"key":"386_CR28","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1124\/jpet.105.097824","volume":"318","author":"BD Green","year":"2006","unstructured":"Green BD, Lavery KS, Irwin N, O\u2019Harte FP, Harriott P, Greer B, Bailey CJ, Flatt PR. Novel GLP-1 analogue (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta cell function after 3\u00a0weeks daily administration in obese diabetic (ob\/ob) mice. J Pharmacol Exp Ther. 2006;318:914\u201321.","journal-title":"J Pharmacol Exp Ther"},{"key":"386_CR29","doi-asserted-by":"crossref","first-page":"9287","DOI":"10.1158\/0008-5472.CAN-10-2664","volume":"70","author":"Y Zhao","year":"2010","unstructured":"Zhao Y, McLaughlin D, Robinson E, Harvey AP, Hookham MB, Shah AM, McDermott BJ, Grieve DJ. Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with doxorubicin chemotherapy. Cancer Res. 2010;70:9287\u201397.","journal-title":"Cancer Res"},{"key":"386_CR30","doi-asserted-by":"crossref","first-page":"C270","DOI":"10.1152\/ajpcell.00194.2015","volume":"310","author":"J Du","year":"2016","unstructured":"Du J, Zhang L, Wang Z, Yano N, Zhao YT, Wei L, Dubielecka-Szczerba P, Liu PY, Zhuang S, Qin G, Zhao TC. Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted hearts. Am J Physiol Cell Physiol. 2016;310:C270\u201383.","journal-title":"Am J Physiol Cell Physiol"},{"key":"386_CR31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12933-014-0132-9","volume":"13","author":"YM Tsutsumi","year":"2014","unstructured":"Tsutsumi YM, Tsutsumi R, Hamaguchi E, Sakai Y, Kasai A, Ishikawa Y, Yokoyama U, Tanaka K. Exendin-4 ameliorates cardiac ischemia\/reperfusion injury via caveolae and caveolins-3. Cardiovasc Diabetol. 2014;13:132.","journal-title":"Cardiovasc Diabetol"},{"key":"386_CR32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.molmet.2014.04.009","volume":"3","author":"JR Ussher","year":"2014","unstructured":"Ussher JR, Baggio LL, Campbell JE, Mulvihill EE, Kim M, Kabir MG, Cao X, Baranek BM, Stoffers DA, Seeley RJ, Drucker DJ. Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. Mol Metab. 2014;3:507\u201317.","journal-title":"Mol Metab"},{"key":"386_CR33","doi-asserted-by":"crossref","first-page":"H2401","DOI":"10.1152\/ajpheart.00347.2005","volume":"289","author":"LA Nikolaidis","year":"2005","unstructured":"Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005;289:H2401\u20138.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"386_CR34","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/hh1501.094396","volume":"89","author":"EE Creemers","year":"2001","unstructured":"Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res. 2001;89:201\u201310.","journal-title":"Circ Res"},{"key":"386_CR35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pharmthera.2013.03.009","volume":"139","author":"GV Halade","year":"2013","unstructured":"Halade GV, Jin YF, Lindsey ML. Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther. 2013;139:32\u201340.","journal-title":"Pharmacol Ther"},{"key":"386_CR36","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00395-014-0444-7","volume":"109","author":"V Kain","year":"2014","unstructured":"Kain V, Prabhu S, Halade G. Inflammation revisited: inflammation versus resolution of inflammation following myocardial infarction. Basic Res Cardiol. 2014;109:444.","journal-title":"Basic Res Cardiol"},{"key":"386_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-015-0518-1","volume":"111","author":"M Tate","year":"2016","unstructured":"Tate M, Robinson E, Green BD, McDermott BJ, Grieve DJ. Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages. Basic Res Cardiol. 2016;111:1.","journal-title":"Basic Res Cardiol"},{"key":"386_CR38","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/HCO.0000000000000158","volume":"30","author":"NG Frangogiannis","year":"2015","unstructured":"Frangogiannis NG. Inflammation in cardiac injury, repair and regeneration. Curr Opin Cardiol. 2015;30:240\u20135.","journal-title":"Curr Opin Cardiol"},{"key":"386_CR39","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pharmthera.2009.05.002","volume":"123","author":"KE Porter","year":"2009","unstructured":"Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther. 2009;123:255\u201378.","journal-title":"Pharmacol Ther"},{"key":"386_CR40","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2337\/db09-1694","volume":"59","author":"M Arakawa","year":"2010","unstructured":"Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010;59:1030\u20137.","journal-title":"Diabetes"},{"key":"386_CR41","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1111\/j.1582-4934.2009.00707.x","volume":"13","author":"C Troidl","year":"2009","unstructured":"Troidl C, Mollmann H, Nef H, Masseli F, Voss S, Szardien S, Willmer M, Rolf A, Rixe J, Troidl K, Kostin S, Hamm C, Elsasser A. Classically and alternatively activated macrophages contribute to tissue remodelling after myocardial infarction. J Cell Mol Med. 2009;13:3485\u201396.","journal-title":"J Cell Mol Med"},{"key":"386_CR42","doi-asserted-by":"crossref","first-page":"C508","DOI":"10.1152\/ajpcell.00248.2012","volume":"304","author":"CW Younce","year":"2013","unstructured":"Younce CW, Burmeister MA, Ayala JE. Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a. Am J Physiol Cell Physiol. 2013;304:C508\u201318.","journal-title":"Am J Physiol Cell Physiol"},{"key":"386_CR43","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.bbrc.2015.09.179","volume":"468","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, He X, Chen Y, Huang Y, Wu L, He J. Exendin-4 attenuates cardiac hypertrophy via AMPK\/mTOR signaling pathway activation. Biochem Biophys Res Commun. 2015;468:394\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"386_CR44","doi-asserted-by":"crossref","first-page":"e58445","DOI":"10.1371\/journal.pone.0058445","volume":"8","author":"A Liberman","year":"2013","unstructured":"Liberman A, Esser M, Marx N, Burgmaier M. Glucagon-like peptide-1(9\u201336) inhibits chemokine-induced migration of human CD4-positive lymphocytes. PLoS ONE. 2013;8:e58445.","journal-title":"PLoS ONE"},{"key":"386_CR45","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/CIRCULATIONAHA.112.001357","volume":"128","author":"S Heymans","year":"2013","unstructured":"Heymans S, Corsten MF, Verhesen W, Carai P, van Leeuwen RE, Custers K, Peters T, Hazebroek M, Stoger L, Wijnands E, Janssen BJ, Creemers EE, Pinto YM, Grimm D, Schurmann N, Vigorito E, Thum T, Stassen F, Yin X, Mayr M, de Windt LJ, Lutgens E, Wouters K, de Winther MP, Zacchigna S, Giacca M, van Bilsen M, Papageorgiou AP, Schroen B. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation. 2013;128:1420\u201332.","journal-title":"Circulation"},{"key":"386_CR46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/FJC.0000000000000255","volume":"66","author":"R Wang","year":"2015","unstructured":"Wang R, Lu L, Guo Y, Lin F, Chen H, Chen W, Chen M. Effect of glucagon-like peptide-1 on high-glucose-induced oxidative stress and cell apoptosis in human endothelial cells and its underlying mechanism. J Cardiovasc Pharmacol. 2015;66:135\u201340.","journal-title":"J Cardiovasc Pharmacol"},{"key":"386_CR47","doi-asserted-by":"crossref","first-page":"13701","DOI":"10.1523\/JNEUROSCI.2107-12.2012","volume":"32","author":"T Ma","year":"2012","unstructured":"Ma T, Du X, Pick JE, Sui G, Brownlee M, Klann E. Glucagon-like peptide-1 cleavage product GLP-1(9\u201336) amide rescues synaptic plasticity and memory deficits in Alzheimer\u2019s disease model mice. J Neurosci. 2012;32:13701\u20138.","journal-title":"J Neurosci"},{"key":"386_CR48","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1089\/ars.2006.8.691","volume":"8","author":"AC Cave","year":"2006","unstructured":"Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, Shah AM. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal. 2006;8:691\u2013728.","journal-title":"Antioxid Redox Signal"},{"key":"386_CR49","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2337\/db15-1224","volume":"65","author":"EE Mulvihill","year":"2016","unstructured":"Mulvihill EE, Varin EM, Ussher JR, Campbell JE, Bang KW, Abdullah T, Baggio LL, Drucker DJ. Inhibition of dipeptidyl peptidase-4 impairs ventricular function and promotes cardiac fibrosis in high fat-fed diabetic mice. Diabetes. 2016;65:742\u201354.","journal-title":"Diabetes"},{"key":"386_CR50","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.2337\/db14-1708","volume":"64","author":"E Tomas","year":"2015","unstructured":"Tomas E, Stanojevic V, McManus K, Khatri A, Everill P, Bachovchin WW, Habener JF. GLP-1(32-36)amide pentapeptide increases basal energy expenditure and inhibits weight gain in obese mice. Diabetes. 2015;64:2409\u201319.","journal-title":"Diabetes"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-016-0386-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T06:59:34Z","timestamp":1498287574000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-016-0386-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,14]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["386"],"URL":"https:\/\/doi.org\/10.1186\/s12933-016-0386-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,14]]},"article-number":"65"}}